Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yoshihiro Fukumoto has a total of 498 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Kidney Function Variability and Cardiovascular Outcomes in Heart Failure: Effects of Empagliflozin in the EMPEROR-Reduced Trial

    by Masayuki Kunitake, Kyoko Higuchi, Yoshiro Sakai, Yoshihiro Fukumoto

    Background: Although sodium-glucose cotransporter-2 (SGLT2) inhibitors improve cardiovascular and kidney outcomes in patients with heart failure (HF), the prognostic significance of intraindividual kidney function variability and its modification by SGLT2 inhibition remain unclear. We investigated these relationships in patients with HF with reduced ejection fraction (HFrEF). Methods: This secondary analysis included 3,492 patients from the EMPEROR-Reduced trial. A location-scale joint model (LSJM) simultaneously evaluated the associations of estimated glomerular filtration rate (eGFR) levels, longitudinal slopes, and intraindividual variability from day 28 onward with the composite outcome of cardiovascular death or HF hospitalization. Patients were stratified into tertiles of estimated eGFR variability using common cutoffs across the empagliflozin and placebo groups, allowing comparisons of cardiovascular outcomes at comparable variability levels. Results: Greater intraindividual eGFR variability was independently associated with increased cardiovascular risk (hazard ratio: 1.08 per 1 mL/min/1.73 m2 increase in estimated standard deviation; P < 0.001). The model incorporating eGFR levels, slopes, and variability demonstrated the best fit. Empagliflozin significantly reduced eGFR variability compared with placebo (standard deviation ratio: 0.93; P = 0.005) and attenuated annual eGFR decline by 1.83 mL/min/1.73 m2/year, despite an initial eGFR reduction of approximately 2.5 mL/min/1.73 m2. Event-free survival progressively decreased with increasing eGFR variability in both treatment groups. Importantly, within each variability tertile defined by common cutoffs, empagliflozin-treated patients consistently exhibited higher event-free survival than placebo-treated patients. Conclusion: In patients with HFrEF, greater intraindividual eGFR variability was independently associated with adverse cardiovascular outcomes, beyond eGFR levels and slopes. Empagliflozin reduced kidney function variability and attenuated long-term eGFR decline, with more favorable cardiovascular outcomes observed even among patients with comparable levels of kidney function variability.

  • Open Access

    Sex Differences in Clinical Presentation and Outcomes in Chronic Thromboembolic Pulmonary Hypertension

    by Keiji Kimuro, Kohei Masaki, Masayuki Hirose, Takumi Inami, Yu Taniguchi, Shiro Adachi, Kazuya Hosokawa, Jun Yamashita, Taijyu Satoh, Junichi Nakamura, et al.

  • Open Access

    Delivery of cardiac rehabilitation through hybrid models and alternative settings by country income classification and decade: Comparisons from the International Council of Cardiovascular Prevention and Rehabilitation’s 2025 Global Audit Update

    by Gabriela L. M. Ghisi, Rachael P. Carson, Karam Turk Adawi, Rongjing Ding, Monserrat Cruz Rivero, Claudia V. Anchique, Dinah L. van Schalkwijk, Jonathan Gallagher, Chamila Mettananda, Rosalia Fernández, et al.

    Objective: Cardiac rehabilitation (CR) is an outpatient model of secondary prevention that improves patient outcomes, yet use remains limited. Hybrid/alternative CR addresses these challenges, but global availability, structure, and volumes have not been characterized since the pandemic. Methods: The International Council of Cardiovascular Prevention and Rehabilitation’s (ICCPR) 2025 Audit Update is a cross-sectional survey of phase II CR programs worldwide. After member Associations supported identification of countries with CR, program data were collected via REDCap between May-September/2025. Data were compared by country income classification, and with prior ICCPR Audits where possible. Results: Of 6,905 CR programs identified globally, 1,505 initiated a survey (median program response rate = 62.3% per country) from 90/113 (79.6%) countries with CR. Globally, 286 (23.2%) programs in 40 (35.4%) countries reported reimbursement for hybrid/alternative models, varying significantly by country income class (p < 0.001); this was higher than 2016 (14.5%), but not significantly different from the pandemic (21.0%). 285 (31.1%) programs reported offering a hybrid/alternative CR model, in 57 (50.4% with CR) countries (higher in lower-middle income countries, then upper-middle income countries [UMICs]). This was not higher than previous Audits. Programs were staffed by exercise professionals, nurses and physicians (more in UMICs). Dose was a median of 10 sessions (one/week over 8 weeks), lower than centre-based, but consistent across income classes and over time. Patients were allocated to model based on clinical criteria, choice (69.5%), but also cost (30.2%; higher in middle-income countries and than 2016). Hybrid/alternative models served a median of 50 (P25-P75 = 10–100) patients/program annually, lower than centre-based (median = 135; p < 0.001); volumes were higher in UMICs. 160 (45.8%) programs perceived insufficient capacity to meet demand, most commonly due to staffing and funding. Conclusions: Hybrid/alternative CR availability has not increased since 2016, and decreased since the pandemic. Reimbursement drives availability, but remains limited and inadequate, frequently shifting costs to patients, constraining services and limiting equitable scale-up.

  • Open Access

    Strategy Selection and Outcomes of Tip-Detection in CTO-PCI

    by Kazunori Yamaji, Kota Tanaka, Tomohiro Yamasaki, Yoshitomo Tsutsui, Kiwamu Sudo, Satoshi Watanabe, Mutsumi Iwamoto, Nobuaki Tanaka, Yasushi Koyama, Yoshitaka Iwanaga, et al.

  • Open Access

    The Role of Medical Therapy Before and After Balloon Pulmonary Angioplasty: CTEPH AC Registry Across Japan

    by Miki Sakamoto‐Iwata, Yu Taniguchi, Kohei Masaki, Kazuya Hosokawa, Shiro Adachi, Takumi Inami, Jun Yamashita, Hitoshi Ogino, Masaru Hatano, Ichizo Tsujino, et al.

    We aimed to evaluate the role of medical therapy before and after balloon pulmonary angioplasty (BPA) for non‐operable chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era. This Japanese nationwide, multicenter, prospective observational registry, including 37 centers, analyzed data newly registered from August 2018–December 2023. Pretreatment before BPA was analyzed in patients who were treatment naïve or received medical therapy only at registration ( n = 557). De‐escalation or escalation of medical therapy after BPA was analyzed in patients who underwent BPA ( n = 966). The BPA pretreatment analysis in 557 patients showed that approximately 70% of the patients received medical therapy, of which 18% received combination therapy. Patients who received monotherapy or combination therapy had more severe baseline hemodynamics than those who did not. The 3‐year survival did not significantly differ between the no, mono, and combination pretreatment groups (94%, 98%, and 97%, respectively; p = 0.852). The BPA post‐treatment analysis in 966 patients showed that 20% of patients underwent de‐escalation of medical therapy. Patients with de‐escalation of medical therapy had lower mean pulmonary artery pressure (PAP) (20.9 ± 5.8 vs. 24.1 ± 7.3 mmHg, p < 0.01); however, they had a lower cardiac index at last follow‐up compared to patients without de‐escalation (2.66 ± 0.61 vs. 2.84 ± 0.70 L/min/m 2 , p = 0.01). Patients with severe disease tended to undergo pre‐treatment before BPA; however, patient survival did not differ across pretreatment types. De‐escalation of medical therapy after BPA can affect cardiac index. Therefore, de‐escalation or continuation of medical therapy should be carefully considered even after mean PAP normalizes after BPA.


  • Open Access

    Cardiac rehabilitation referral and access by country income class: Comparisons from the International Council of Cardiovascular Prevention and Rehabilitation’s 2025 Global Audit Update

    by Rachael P. Carson, Sherry L. Grace, Karam Turk Adawi, Mariya P. Jiandani, Lilian Mbau, Jimena Martinez, Monserrat Cruz Rivero, Claudia V. Anchique, Rongjing Ding, Dinah L. van Schalkwijk, et al.


  • Open Access

    Facilitating early diagnosis of chronic thromboembolic pulmonary hypertension with dynamic chest radiography: Protocol for a multicenter, assessor-blinded, case-wise randomized superiority reader study (FIND-DCR)

    by Kazuya Hosokawa, Yuzo Yamasaki, Junji Kishimoto, Tomomi Nagayama, Shiro Adachi, Shinji Naganawa, Takumi Inami, Kenichi Yokoyama, Satoshi Yasuda, Kei Takase, et al.

    Introduction: Chronic thromboembolic pulmonary hypertension (CTEPH) is a treatable cause of pulmonary hypertension but remains under-recognized and is often diagnosed with delay. Limited access to lung ventilation-perfusion (V/Q) scintigraphy, especially outside tertiary centers, is one contributor. Dynamic chest radiography (DCR), with a pulmonary circulation analysis program, can provide a rapid, non-invasive, and widely deployable assessment of pulmonary perfusion. We describe the protocol of a multicenter reader study testing whether adding DCR-based analysis to standard initial work-up improves diagnostic accuracy for CTEPH among patients with echocardiographically suspected pulmonary hypertension. Methods and analysis: This investigator-initiated, multicenter, assessor-blinded, case-wise randomized superiority reader study compares standard initial work-up (blood tests, chest X-ray, ECG, pulmonary function tests, and transthoracic echocardiography per guidelines) with standard work-up plus DCR-based pulmonary circulation analysis. The primary endpoint is diagnostic accuracy for discrimination between CTEPH and non-CTEPH in the intention-to-treat set. The final diagnosis of CTEPH versus non-CTEPH will be defined as the reference standard according to the Japanese and European guidelines for pulmonary hypertension. Secondary endpoints include sensitivity, specificity, positive and negative predictive values; agreement with V/Q scintigraphy regarding regional perfusion defects using κ statistics; and STARD-conformant academic performance evaluation of DCR-based pulmonary circulation analysis and lung perfusion scintigraphy in relation to the site-level final diagnosis of CTEPH versus non-CTEPH in a full analysis set. Safety endpoints include adverse events during DCR acquisition and device malfunctions. The target sample size is 108 cases with 1:1 allocation. Recruitment started on 30/07/2025 and is expected to continue until 28/02/2027, with overall study completion planned for 31/05/2027. Discussion: This multicenter reader study addresses a key limitation of current CTEPH diagnostic pathways—reliance on V/Q scintigraphy, which may be delayed or unavailable outside tertiary centers—by evaluating whether DCR-based pulmonary circulation analysis can improve early discrimination of CTEPH and support timely referral. Trial registration number: Japan Registry of Clinical Trials (jRCT), jRCT2072250027.